| 孙照兴1，李一权2，汪伟1，李文杰1▲.肝细胞癌免疫治疗研究进展[J].中国医药科学,2025,(5):25-28 基金项目:吉林省教育厅科学技术研究项目（JJKH20220873KJ） |
| 肝细胞癌免疫治疗研究进展 |
| Research progress of immunotherapy for hepatocellular carcinoma |
| |
| DOI： |
| 中文关键词: 肝细胞癌；免疫检查点抑制剂；CAR-T疗法；溶瘤病毒；肿瘤疫苗 |
| 英文关键词:Hepatocellular carcinoma; Immune checkpoint inhibitor; CAR-T therapy; Oncolytic virus; Tumor vaccine |
| 作者 | 单位 | | 孙照兴1，李一权2，汪伟1，李文杰1▲ | 1.温州大学病毒学研究所，浙江温州 325000；2.长春中医药大学吉林省院士工作站，吉林长春 130177 |
|
| 摘要点击次数: 32 |
| 全文下载次数: 20 |
| 中文摘要: |
| [摘要] 肝细胞癌（HCC）是一种发病隐匿、预后差、发病率和病死率均较高的恶性肿瘤。在过去，索拉非尼等分子靶向药物是HCC系统治疗的主要手段，但仅能提供有限的生存获益。近年来，随着癌症免疫治疗领域的发展，免疫疗法为HCC提供了新的治疗方法。阿替利珠单抗联合贝伐单抗显示出显著的生存改善，免疫检查点抑制剂联合分子靶向药以及双免疫检查点联合疗法也取得令人满意的结果。此外，嵌合抗原受体T细胞、溶瘤病毒和肿瘤疫苗等治疗策略也处于早期临床试验阶段，用于HCC的治疗。本文主要针对目前已经和正在开发的HCC免疫疗法进行简要的回顾和概述。 |
| 英文摘要: |
| [Abstract] Hepatocellular carcinoma (HCC) is a malignant tumor with occult onset, poor prognosis and high morbidity and mortality. In the past, molecular targeted drugs such as sorafenib have been the main means of systematic treatment of HCC, but they can only provide limited survival benefits. In recent years, with the development of cancer immunotherapy, immunotherapy has provided a new treatment for HCC. The combination of atilizumab and bevacizumab showed a significant improvement in survival, and the combination of immune checkpoint inhibitor and double immune checkpoints also achieved satisfactory results. In addition, chimeric antigen receptor T cells, oncolytic virus and tumor vaccine are also in the early clinical trial stage for the treatment of HCC. This paper briefly reviews and summarizes the immunotherapy for HCC that has been and is being developed at present. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
.jpg)